Evidence map›Paper›PMID 28600399›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2017

Validation of PDE5 as a Chemoprevention Target.

Gary A Piazza

Abstract readEditorialComment
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Gary A PiazzaUniversity of South Alabama Mitchell Cancer Institute, Mobile, Alabama. gpiazza@health.southalabama.edu.

Funding

Selective anti-cancer activity of sulindac derivatives on KRAS mutant colon tumor cells by inducing ROSR01CA131378 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI PIAZZA, GARY A · 2008 to 2019
$5.2M
Development of a novel sulindac amide for colorectal cancer chemopreventionR01CA148817 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI PIAZZA, GARY A · 2010 to 2015
$2.4M
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer ChemopreventionR01CA155638 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI PIAZZA, GARY A · 2012 to 2017
$2.3M
Phosphodiesterase 10A, a novel target for lung cancer chemopreventionR01CA197147 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI PIAZZA, GARY A · 2016 to 2020
$1.9M
NCI NIH HHS R01 CA131378NCI NIH HHS R01 CA148817NCI NIH HHS R01 CA155638NCI NIH HHS R01 CA197147
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Colorectal NeoplasmsSildenafil CitrateAnimalsChemopreventionColonic NeoplasmsInflammationMiceSildenafil Citrate

Identifiers

PMID28600399
PMCPMC5521204

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.